Patient Invoice Payment Link
Contact Us

Advanced Wound PCR Panel

Comprehensive, Rapid, and Clinically Actionable Detection

Transforming Wound Care with Molecular Diagnostics

Chronic and acute wound infections are often polymicrobial, involve biofilm-producing organisms, and may harbor antimicrobial resistance (AMR)—making them difficult to diagnose and treat using traditional methods.

Our comprehensive Wound PCR Panel provides rapid, highly sensitive detection of bacterial, fungal, and resistance markers—empowering clinicians to deliver targeted, effective therapy faster.

Wound Pathogen Panel

Bacteria
27 targets
Acinetobacter baumannii
Bac (gram-negative)
Actinotignum schaalii
Bac (gram-positive)
Aerococcus urinae
Bac (gram-positive)
Bacteroides fragilis
Bac (gram-negative)
Citrobacter spp. (freundii/braakii/koseri)
Bac (gram-negative)
Enterobacter cloacae
Bac (gram-negative)
Enterococcus faecalis
Bac (gram-positive)
Enterococcus faecium
Bac (gram-positive)
Escherichia coli
Bac (gram-negative)
Klebsiella (Enterobacter) aerogenes
Bac (gram-negative)
Klebsiella oxytoca
Bac (gram-negative)
Klebsiella pneumoniae
Bac (gram-negative)
Morganella morganii
Bac (gram-negative)
Peptostreptococcus spp. (stomatis/magnus/anaerobius)
Bac (gram-positive)
Prevotella bivia
Bac (gram-negative)
Proteus mirabilis
Bac (gram-negative)
Proteus vulgaris
Bac (gram-negative)
Pseudomonas aeruginosa
Bac (gram-negative)
Serratia marcescens
Bac (gram-negative)
Staphylococcus aureus
Bac (gram-positive)
Staphylococcus epidermidis
Bac (gram-positive)
Staphylococcus haemolyticus
Bac (gram-positive)
Staphylococcus lugdunensis
Bac (gram-positive)
Staphylococcus saprophyticus
Bac (gram-positive)
Stenotrophomonas maltophilia
Bac (gram-negative)
Streptococcus agalactiae (Group-B)
Bac (gram-positive)
Streptococcus pyogenes (Group-A)
Bac (gram-positive)
Fungus
8 targets
Candida albicans
Fungus
Candida auris
Fungus
Candida glabrata
Fungus
Candida lusitaniae
Fungus
Candida parapsilosis
Fungus
Candida tropicalis
Fungus
Epidermophyton floccosum
Fungus
Trichophyton rubrum
Fungus
AMR
16 targets
Class A beta-lactamase resistance (blaKPC)
AMR
Class A beta-lactamase resistance (blaSHV)
AMR
Class A beta-lactamase resistance (blaTEM)
AMR
Class A beta-lactamase resistance (CTX-M-Grp1)
AMR
Class B beta-lactamase resistance (blaNDM-1/blaNDM-4/blaNDM-5/blaNDM-7)
AMR
Class D beta-lactamase resistance (OXA-48/OXA-51)
AMR
Fluoroquinolone resistance (gyrA)
AMR
Fluoroquinolone resistance (qnrA/qnrB/qnrS)
AMR
Methicillin resistance (mecA)
AMR
Sulfonamide resistance (sul1)
AMR
Tetracycline resistance (tetB)
AMR
Tetracycline resistance (tetM)
AMR
Trimethoprim resistance (dfrA1)
AMR
Vancomycin resistance (vanA)
AMR
Vancomycin resistance (vanB)
AMR
Vancomycin resistance (vanM)
AMR

Comprehensive Pathogen Coverage

Gram-Positive & Gram-Negative Bacteria

Includes clinically significant organisms commonly associated with:

  • Diabetic foot ulcers
  • Surgical site infections
  • Chronic non-healing wounds

Key pathogens detected:

  • Staphylococcus aureus, S. epidermidis, S. lugdunensis
  • Streptococcus pyogenes, S. agalactiae
  • Enterococcus faecalis, E. faecium
  • Pseudomonas aeruginosa
  • Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae
  • Proteus, Morganella, Serratia
  • Anaerobes like Bacteroides fragilis and Peptostreptococcus spp.

Full organism list confirmed in panel specification (page 1)

Fungal Pathogens

Critical for identifying mixed infections and treatment-resistant wounds:

  • Candida species (including C. auris)
  • Dermatophytes (Trichophyton rubrum, Epidermophyton floccosum)

Fungal targets detailed on page 1

Antimicrobial Resistance (AMR) Markers

This panel goes beyond detection—it identifies resistance genes driving treatment failure:

  • Beta-lactamases: blaKPC, blaSHV, blaTEM, CTX-M
  • Carbapenem resistance: NDM variants, OXA-48/51
  • Methicillin resistance: mecA
  • Vancomycin resistance: vanA, vanB, vanM
  • Fluoroquinolone resistance: gyrA, qnr genes
  • *Tetracycline, sulfonamide, trimethoprim resistance

Complete AMR panel detailed on page 2

Clinical Utility: Why This Panel Matters

1. Detects Polymicrobial Infections Missed by Culture

  • Chronic wounds frequently contain multiple aerobic and anaerobic organisms
  • PCR identifies all pathogens simultaneously, including:
  • Fastidious organisms
  • Low-abundance pathogens
  • Biofilm-associated bacteria

2. Rapid Results Drive Faster Clinical Decisions

  • Traditional cultures: 48–96+ hours
  • PCR results: ~24 hours
  • Enables earlier targeted therapy, reducing:
  • Infection progression
  • Hospitalization risk
  • Amputation rates

3. Identifies Resistance Before Treatment Failure

  • Direct detection of AMR genes allows:
  • Proactive antibiotic selection
  • Avoidance of ineffective therapies
  • Improved antimicrobial stewardship

4. Improves Outcomes in Chronic & Non-Healing Wounds

  • Ideal for:
  • Diabetic foot ulcers
  • Pressure ulcers
  • Venous stasis ulcers
  • Post-surgical infections
  • Burn wounds
  • Supports faster wound closure and reduced recurrence

5. Detects Fungal Co-Infections Often Overlooked

  • Fungal pathogens can:
  • Delay healing
  • Mimic bacterial infection
  • PCR ensures comprehensive microbial assessment

6. Enhances Antibiotic Stewardship

  • Reduces empiric broad-spectrum antibiotic use
  • Aligns therapy with specific pathogens + resistance profile
  • Helps combat antibiotic resistance trends

Clinical Scenarios Where This Panel Excels

Non-healing chronic wounds despite antibiotics

Recurrent infections with unclear etiology

Negative or inconclusive culture results

Suspected multidrug-resistant infections

Complex polymicrobial infections

Key Advantages at a Glance

Broad bacterial + fungal coverage

Integrated AMR detection

Rapid turnaround (~24 hours)

High sensitivity vs. culture

Detects biofilm-associated organisms

Supports precision therapy

Elevating Wound Care Through Precision Diagnostics

With the ability to detect pathogens + resistance markers in a single test, this Wound PCR Panel provides clinicians with the tools needed to:

Make faster, evidence-based treatment decisions

Reduce treatment failures and complications

Improve healing rates and patient outcomes